Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent Relating to Prolactin
February 10 2011 - 12:00PM
Marketwired
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the
"Company") is pleased to announce today that it has been granted a
patent by the U.S. Patent and Trademark Office -U.S. Patent
7,884,072- entitled, "Prolactin induced increase in neural stem
cell number." The claims contained within this issued patent cover
methods of using an effective amount of prolactin to increase stem
cell numbers in mammals suspected of having neurological diseases.
Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as
follows:
"This issued patent and other anticipated patents for the use of
prolactin greatly assist the protection and capture of shareholder
value for this therapeutic program. The important exclusivity that
has been granted for the use of prolactin today combined with ever
increasing scientific evidence supporting the use of prolactin
builds upon the wealth of intellectual property that SCT possesses.
We look forward to the continued advancement of this program in the
future."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a public biotechnology company (TSX VENTURE: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development
of therapies that utilize drugs to stimulate a patient's own
resident stem cells. The Company's programs aim to repair brain and
nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, and ALS.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Allen Davidoff, PhD CSO
403-245-5495 ext.226 adavidoff@stemcellthera.com Stem Cell
Therapeutics Corp. Michael Cook CFO 403-245-5495 ext.229
mcook@stemcellthera.com Stem Cell Therapeutics Corp. Angelika
Goncalves DaSilva Operations Manager 403-245-5495 ext. 230
adasilva@stemcellthera.com www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024